Compare EXFY & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXFY | OTLK |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.0M | 249.6M |
| IPO Year | 2021 | 2016 |
| Metric | EXFY | OTLK |
|---|---|---|
| Price | $2.45 | $0.57 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.83 | ★ $5.03 |
| AVG Volume (30 Days) | 455.0K | ★ 3.5M |
| Earning Date | 11-05-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,101,000.00 | $8,146,123.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.15 | $6,355.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.06 | N/A |
| 52 Week Low | $0.69 | $0.16 |
| 52 Week High | $2.81 | $2.54 |
| Indicator | EXFY | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 57.97 | 35.64 |
| Support Level | $2.05 | $0.52 |
| Resistance Level | $2.80 | $0.70 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 95.18 | 25.27 |
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.